Abstract
Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).
Keywords: akt, pi3k, androgen receptor, mapk, pten, prostate cancer
Current Drug Metabolism
Title: Akt in Prostate Cancer: Possible Role in Androgen-Independence
Volume: 4 Issue: 6
Author(s): Paramita M. Ghosh, Shazli Malik, Roble Bedolla and Jeffrey I. Kreisberg
Affiliation:
Keywords: akt, pi3k, androgen receptor, mapk, pten, prostate cancer
Abstract: Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), has often been implicated in prostate cancer. Studies in prostate tumor cell lines revealed that Akt activation is probably important for the progression of prostate cancer to an androgen-independent state. Investigations of human prostate cancer tissues show that although there is neither Akt gene amplification nor enhanced protein expression in prostate cancer compared to normal tissue, poorly differentiated tumors exhibit increased expression of a phosphorylated (activated) form of Akt compared to normal tissue, prostatic intraepithelial neoplasia (PIN) or well-differentiated prostate cancer. Akt phosphorylation is accompanied by the inactivation of ERK, a member of the mitogen activated protein kinase (MAPK) family. In this article, we postulate that Akt promotes androgen-independent survival of prostate tumor cells by modulating the expression and activation of the androgen receptor (AR).
Export Options
About this article
Cite this article as:
Ghosh M. Paramita, Malik Shazli, Bedolla Roble and Kreisberg I. Jeffrey, Akt in Prostate Cancer: Possible Role in Androgen-Independence, Current Drug Metabolism 2003; 4 (6) . https://dx.doi.org/10.2174/1389200033489226
DOI https://dx.doi.org/10.2174/1389200033489226 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SPR Imaging for High Throughput, Label-Free Interaction Analysis
Combinatorial Chemistry & High Throughput Screening Antiproliferative Activities on Renal, Prostate and Melanoma Cancer Cell Lines of Sarcopoterium spinosum Aerial Parts and its Major Constituent Tormentic Acid
Anti-Cancer Agents in Medicinal Chemistry CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets MicroRNAs in Organogenesis and Disease
Current Molecular Medicine Dietary Approaches and Alternative Therapies for Polycystic Ovary Syndrome
Current Nutrition & Food Science Developments in Selective Small Molecule ATP-Targeting the Serine/Threonine Kinase Akt/PKB
Mini-Reviews in Medicinal Chemistry Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers
Clinical Cancer Drugs Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Inhibition of P450 17 as a New Strategy for the Treatment of Prostate Cancer
Current Medicinal Chemistry Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Bioactive Peptides from Marine Organisms: A Short Overview
Protein & Peptide Letters A Comparison of Fucoidan Conjugated to Paclitaxel and Curcumin for the Dual Delivery of Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Leukopenia Associated with Risperidone Treatment
Current Drug Safety Chemical Consequences of Radioactive Decay and their Biological Implications
Current Radiopharmaceuticals New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Energy Balance and Carcinogenesis: Underlying Pathways and Targets for Intervention
Current Cancer Drug Targets Incorporation of Selenocysteine into Proteins Using Peptide Ligation
Protein & Peptide Letters The Role of miRNAs in the Differentiation of Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Chaperones and Their Role in Telomerase Ribonucleoprotein Biogenesis and Telomere Maintenance
Current Proteomics